The effect of diabetes on oxaliplatin-induced peripheral neuropathy

Clinical Colorectal Cancer

Volumn 11, Issue 4, 2012, Pages 275-279

  Uwah, Augusta N ^a   Ackler, Joan ^b   Leighton, John C ^b   Pomerantz, Sherry ^b   Tester, William ^b  

^a HOWARD UNIVERSITY HOSPITAL   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

Chemotherapy; Diabetes; Hypertension; Neuropathy

Indexed keywords

EID: 84868381169     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.05.002     Document Type: Article

References (21)

1. P.C. Simmonds Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis Colorectal Cancer Collaborative Group BMJ 321 2000 531 535
2. A. de Gramont, A. Figer, M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
3. H.P. Kalofonos, G. Aravantinos, P. Kosmidis Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study Ann Oncol 16 2005 869 877
4. S. Sharif, M.J. O'Connell, G. Yothers FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer Cancer Invest 26 2008 956 963
5. C.L. Attard, J.A. Maroun, K. Alloul Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada Curr Oncol 17 2010 17 24
6. L. Raftery, R.M. Goldberg Optimal delivery of cytotoxic chemotherapy for colon cancer Cancer J 16 2010 214 219
7. G. Masi, F. Loupakis, L. Salvatore Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 2010 845 852
8. R. Zarate, J. Rodríguez, E. Bandres Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis Br J Cancer 102 2010 987 994
9. J. Ocvirk, T. Brodowicz, F. Wrba Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial World J Gastroenterol 16 2010 3133 3143
10. C. Siau, G.J. Bennett Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy Anesth Analg 102 2006 1485 1490
11. A.A. Argyriou, P. Polychronopoulos, G. Iconomou A review on oxaliplatin-induced peripheral nerve damage Cancer Treat Rev 34 2008 368 377
12. G. Kannarkat, E.E. Lasher, D. Schiff Neurologic complications of chemotherapy agents Curr Opin Neurol 20 2007 719 725
13. R. Kirchmair, D.H. Walter, M. Ii Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth Circulation 111 2005 2662 2670
14. G. Comi, M. Corbo Metabolic neuropathies Curr Opin Neurol 11 1998 523 529
15. National Cancer Institute, Cancer Therapy Evaluation Program Common toxicity criteria for Adverse events. Version 4.03 2009 National Cancer Institute Bethesda, MD
16. L. Gamelin, M. Boisdron-Celle, R. Delva Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer Clin Cancer Res 10 2004 4055 4061
17. R.K. Ramanathan, M.L. Rothenberg, A. de Gramont Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies Ann Oncol 21 2010 754 758
18. O. Muto, H. Ando, T. Ono Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions [in Japanese] Gan To Kagaku Ryoho 34 2007 579 581
19. H.S. Hochster, A. Grothey, B.H. Childs Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity J Clin Oncol 25 2007 4028 4029
20. H.S. Hochster, A. Grothey, A. Shpilsky Effect of intravenous (IV) calcium and mangnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial Gastrointestinal Cancers Symposium 2008 Abstract 280
21. C. Tournigand, A. Cervantes, A. Figer OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study J Clin Oncol 24 2006 394 400